On Tuesday, Barrick Gold Corporation (USA) (NYSE:ABX)’s shares inclined 3.47% to $7.59.
ABX offered 12.40% EPS for prior five years. The company has -30.40% return on equity value while its ROI ratio was -9.30%. The company has $8.33 billion market capitalizations and the institutional ownership was 72.10%. Its price to book ratio was 0.91. Volatility of the stock was 4.37% for the week while for the month booked as 4.78%. The mean estimate for the short term price target for Barrick Gold Corporation (USA) (NYSE:ABX) stands at $9.28 according to 21 Analysts. The higher price target estimate for the stock has been calculated at $13.00 while the lower price target estimate is at $7.15. Barrick Gold Corporation (USA) (NYSE:ABX) is a gold mining company. The Company is engaged in the production and sale of gold and copper, as well as related activities, such as exploration and mine development. The Company operates in segments: eight individual gold mines, Acacia and Pascua-Lama project.
Cypress Semiconductor Corporation (NASDAQ:CY)’s shares dropped -0.37% to $10.78.
CY has beta value of 1.82. The company has the market capitalization of $3.52 billion. Return on assets ratio of the company was -9.20% while its return on equity ratio was -13.80%. ATR value of company was 0.30 while stock volatility for week was 2.45% while for month was 2.58%. Debt to equity ratio of the company was 0.22 and its current ratio was 1.60. The mean estimate for the short term price target for Cypress Semiconductor Corporation (NASDAQ:CY) stands at $13.05 according to 11 Analysts. The higher price target estimate for the stock has been calculated at $18 while the lower price target estimate is at $10.00. Cypress Semiconductor Corporation (NASDAQ:CY) is a provider of mixed-signal programmable solutions. The Company’s offerings include PSoC 1, PSoC 3, PSoC 4 and PSoC 5LP programmable system-on-chip families. It caters to markets, including industrial, mobile handsets, consumer, computation, data communications, automotive and military.
At the end of Tuesday’s trade, Orexigen Therapeutics, Inc. (NASDAQ:OREX)‘s shares dipped -4.18% to $2.29.
OREX has market value of $307.89 billion while its EPS was booked as $-0.40 in the last 12 months. The stock has 145.41 million shares outstanding while 88.10% shares of the company were owned by institutional investors. Beta value of the company was 2.63; beta is used to measure riskiness of the security. The mean estimate for the short term price target for Orexigen Therapeutics, Inc. (NASDAQ:OREX) stands at $6.30 according to 5 Analysts. The higher price target estimate for the stock has been calculated at $11.00 while the lower price target estimate is at $4.00. Orexigen Therapeutics, Inc. (NASDAQ:OREX) is a biopharmaceutical company. The Company is focused on the development of pharmaceutical product candidates for the treatment of obesity. The Company’s product is Contrave, a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.